The YC-XLH Advisory Board has been an invaluable source of guidance to the Center, providing both directed scientific input and criticism, and informed lay perspectives. After five years of service, two of the Board’s original members, Ralph Meyer, PhD and Larry Winger, PhD retired; we thank them for their important input over the years.
Michael Collins is chief of the Skeletal Clinical Studies Unit of the Craniofacial and Skeletal Diseases Branch of the National Institute of Dental and Craniofacial Research at the National Institutes of Health. Dr. Collins' primary research interests include the role of FGF23 in bone, fibrous dysplasia of bone, and the clinical consequences of activating GNAS mutations, as occurs in McCune-Albright syndrome (MAS). He was the inaugural recipient of the Fibrous Dysplasia Foundation's Constellation Award in recognition of his outstanding contributions to the care and well-being of people with Fibrous Dysplasia and MAS.Joseph E. Craft, MD
Joseph Craft is the Paul B. Beeson Professor of Medicine (Rheumatology), Professor of Immunobiology, and Chief, Section of Rheumatology at the Yale School of Medicine. He has directed the Yale Investigative Medicine Program, a PhD program for physicians, since 2004. Dr. Craft is an internationally recognized expert on the pathogenesis of systemic autoimmune diseases, investigating both animal models of disease and patients in the clinic, and directs a research laboratory devoted to understanding T lymphocyte differentiation and function in normal and autoimmune responses. He has been continually funded by the NIH since he joined the faculty at Yale in 1985, and is currently an NIH MERIT Award recipient. In addition, Dr. Craft is a fellow of the American Association for the Advancement of Science and a member of the American Society for Clinical Investigation and of the Kunkel Society.Francis H. Glorieux, OC, MD, PhD
Francis Glorieux is an internationally known investigator with more than 35 years experience in the treatment and investigation of genetic and metabolic bone diseases in children. He is the Director of Research (Genetics Unit) at Shriners Hospital for Children in Montreal and Professor of Surgery, Pediatrics and Human Genetics at McGill University. Dr. Glorieux led the initial trials in the 1980s that resulted in the current therapeutic standard of care for X-Linked Hypophosphatemia. He is the recipient of numerous awards and honors in recognition of his outstanding contributions to the pediatric bone field, among them the Bartter Award for Clinical Research from the American Society for Bone and Mineral Research, the Elsevier Award from the International Bone and Mineral Society, and the Order of Canada, the country's highest honor for lifetime achievement.Makoto Kuro-o, MD, PhD
Makoto Kuro-o, Associate Professor of Pathology at University of Texas Southwestern Medical Center, discovered the Klotho gene in 1997. Originally thought to regulate human aging, Klotho has been found to play a critical role in phosphate metabolism, and in particular, the mediation of FGF23 signaling in the kidney. Dr. Kuro-o's primary research interests focus on how endocrine FGFs and Klotho family proteins regulate metabolism and aging. He is a recipient of the President's Research Council Distinguished Young Researcher Award and holds the Kern and Marnie Wildenthal President's Research Council Professorship in Medical Science, both at UT Southwestern.Joan Reed
Joan Reed is a founding member and past president of The XLH Network, Inc., the primary advocacy/support group for people living with X-Linked Hypophosphatemia. A passionate and effective advocate for advancing awareness, diagnosis and treatment of XLH, Ms. Reed's family has a 3-generation history of XLH. Prior to raising her family, and to her involvement with The XLH Network, Inc., she was a legal secretary and a secretary in long-range planning and development at Union Carbide. Today, Ms. Reed and her husband own and operate a restaurant in upstate New York.